Stock listing

Iovance Biotherapeutics, Inc.

Selected listing: A2DT49 · LS · EUR · DE

Iovance Biotherapeutics, Inc. (Lang & Schwarz: A2DT49), Health Technology. Latest release Oct 1, 2026: Iovance Biotherapeutics Appoints Noah Berkowitz, M.D.…

A2DT49:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A2DT49
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: Lang & Schwarz
Currency: EUR

Latest news from Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

September 30, 2026

Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

October 1, 2026

Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million

September 28, 2026

Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026

July 30, 2026

Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

June 3, 2026

All Iovance Biotherapeutics, Inc. news →

Events

Replays

Iovance Biotherapeutics, Inc. (IOVA) Q2 2026 Earnings Call
Thu, Aug 06, 2026 · 08:30 AM ET
Watch
Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call
Thu, May 07, 2026 · 08:30 AM ET
Watch
Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call
Tue, Feb 24, 2026 · 08:30 AM ET
Watch

Research Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. company profile

View the public company page for Iovance Biotherapeutics, Inc. on 6ix.

Iovance Biotherapeutics, Inc. news

Read company news and market updates connected to Iovance Biotherapeutics, Inc..

Iovance Biotherapeutics, Inc. investor events

Find investor webinars, events, and replay context for Iovance Biotherapeutics, Inc..